FI120236B - Kopolymeeri-1 parannuksia kopolymeerien seoksiin - Google Patents

Kopolymeeri-1 parannuksia kopolymeerien seoksiin Download PDF

Info

Publication number: FI120236B
Authority: FI; Finland
Prior art keywords: copolymer; molecular weight; kda; mixture; polypeptides
Prior art date: 1994-05-24

Application number

FI964600A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI964600L (fi

FI964600A0 (fi

Inventor

Eliezer Konfino

Michael Sela

Dvora Teitelbaum

Ruth Arnon

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-24

Filing date

1996-11-15

Publication date

2009-08-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26939072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI120236(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-11-15 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

1996-11-15 Publication of FI964600A0 publication Critical patent/FI964600A0/fi

1996-12-05 Publication of FI964600L publication Critical patent/FI964600L/fi

2009-08-14 Application granted granted Critical

2009-08-14 Publication of FI120236B publication Critical patent/FI120236B/fi

Links

239000000203 mixture Substances 0.000 title claims abstract description 33
229920001577 copolymer Polymers 0.000 title claims description 8
238000000034 method Methods 0.000 claims description 10
108090000765 processed proteins & peptides Proteins 0.000 claims description 9
102000004196 processed proteins & peptides Human genes 0.000 claims description 9
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
229920001184 polypeptide Polymers 0.000 claims description 8
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 8
201000006417 multiple sclerosis Diseases 0.000 claims description 7
238000006243 chemical reaction Methods 0.000 claims description 6
239000000243 solution Substances 0.000 claims description 5
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
235000004279 alanine Nutrition 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
239000004472 Lysine Substances 0.000 claims description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
239000007864 aqueous solution Substances 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
235000013922 glutamic acid Nutrition 0.000 claims description 2
239000004220 glutamic acid Substances 0.000 claims description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims 4
238000004519 manufacturing process Methods 0.000 claims 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
150000001875 compounds Chemical class 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
235000018977 lysine Nutrition 0.000 claims 1
230000035484 reaction time Effects 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
210000004027 cell Anatomy 0.000 description 6
230000001413 cellular effect Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
229960000583 acetic acid Drugs 0.000 description 4
229940076279 serotonin Drugs 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
201000002491 encephalomyelitis Diseases 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
ATCFYQUZTYQTJN-AXDSSHIGSA-N (2s)-2-amino-4-benzylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)CC1=CC=CC=C1 ATCFYQUZTYQTJN-AXDSSHIGSA-N 0.000 description 2
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
208000016557 Acute basophilic leukemia Diseases 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000006386 Myelin Proteins Human genes 0.000 description 2
108010083674 Myelin Proteins Proteins 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
238000003556 assay Methods 0.000 description 2
238000013375 chromatographic separation Methods 0.000 description 2
239000000470 constituent Substances 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229960001340 histamine Drugs 0.000 description 2
229910000042 hydrogen bromide Inorganic materials 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
210000005012 myelin Anatomy 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
KNCHTBNNSQSLRV-YFKPBYRVSA-N (2s)-6-amino-2-[(2,2,2-trifluoroacetyl)amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)C(F)(F)F KNCHTBNNSQSLRV-YFKPBYRVSA-N 0.000 description 1
OFCNTYBPPAQCRE-UHFFFAOYSA-N 3-(2-aminoethyl)-3h-indol-5-ol Chemical compound C1=C(O)C=C2C(CCN)C=NC2=C1 OFCNTYBPPAQCRE-UHFFFAOYSA-N 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
102000047918 Myelin Basic Human genes 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
235000004789 Rosa xanthina Nutrition 0.000 description 1
241000109329 Rosa xanthina Species 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
-1 e.g. Polymers 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
239000003999 initiator Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000013365 molecular weight analysis method Methods 0.000 description 1
239000002362 mulch Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000000379 polymerizing effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000002723 toxicity assay Methods 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Polymers & Plastics (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Rehabilitation Therapy (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Marine Sciences & Fisheries (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Compositions Of Macromolecular Compounds (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Polyamides (AREA)

FI964600A 1994-05-24 1996-11-15 Kopolymeeri-1 parannuksia kopolymeerien seoksiin FI120236B (fi)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US24803794A	1994-05-24	1994-05-24
US24803794		1994-05-24
US34424894A	1994-11-23	1994-11-23
US34424894		1994-11-23
US9506551		1995-05-23
PCT/US1995/006551 WO1995031990A1 (en)	1994-05-24	1995-05-23	Copolymer-1 improvements in compositions of copolymers

Publications (3)

Publication Number	Publication Date
FI964600A0 FI964600A0 (fi)	1996-11-15
FI964600L FI964600L (fi)	1996-12-05
FI120236B true FI120236B (fi)	2009-08-14

Family

ID=26939072

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI964600A FI120236B (fi)	1994-05-24	1996-11-15	Kopolymeeri-1 parannuksia kopolymeerien seoksiin

Country Status (31)

Country	Link
US (11)	US5800808A (no)
EP (1)	EP0762888B1 (no)
JP (2)	JPH10500955A (no)
KR (1)	KR100403750B1 (no)
CN (2)	CN1310673C (no)
AT (1)	ATE212857T1 (no)
AU (1)	AU2602195A (no)
BR (2)	BR9507758A (no)
CA (1)	CA2191088C (no)
CZ (1)	CZ292247B6 (no)
DE (2)	DE69525340T2 (no)
DK (1)	DK0762888T3 (no)
EE (1)	EE03423B1 (no)
ES (1)	ES2172586T3 (no)
FI (1)	FI120236B (no)
GE (1)	GEP20002205B (no)
HK (1)	HK1008657A1 (no)
HU (1)	HU223473B1 (no)
IL (2)	IL113812A (no)
LU (1)	LU90987I2 (no)
MD (1)	MD1443G2 (no)
NL (1)	NL300096I2 (no)
NO (1)	NO324528B1 (no)
NZ (1)	NZ287335A (no)
PL (1)	PL181026B1 (no)
PT (1)	PT762888E (no)
SI (1)	SI0762888T1 (no)
SK (1)	SK283699B6 (no)
TJ (1)	TJ392B (no)
UA (1)	UA62908C2 (no)
WO (1)	WO1995031990A1 (no)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5858980A (en) *	1990-03-30	1999-01-12	Autoimmune, Inc.	Peptide fragments of myelin basic protein
US7090982B2 (en)	1991-10-22	2006-08-15	The Governors Of The University Of Alberta	Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US6252040B1 (en)	1991-10-22	2001-06-26	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5800808A (en)	1994-05-24	1998-09-01	Veda Research And Development Co., Ltd.	Copolymer-1 improvements in compositions of copolymers
US5858964A (en) *	1995-04-14	1999-01-12	Yeda Research And Development Co. Ltd.	Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IL119989A0 (en) *	1997-01-10	1997-04-15	Yeda Res & Dev	Pharmaceutical compositions for oral treatment of multiple sclerosis
HUP0100891A2 (hu) *	1998-02-13	2001-06-28	Autoimmune, Inc.	A COP-1 és Th2 fokozó citokinek gyógyászati alkalmazása
WO2000005249A2 (en)	1998-07-23	2000-02-03	The President And Fellows Of Harvard College	Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) *	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en)	1998-07-23	2002-02-10	Yeda Res & Dev	Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6514938B1 (en)	1998-09-25	2003-02-04	Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ES2369642T3 (es)	1998-09-25	2011-12-02	Yeda Research And Development Co., Ltd.	Polipéptidos relacionados con el copolímero 1 para su uso como marcadores de pesos moleculares y para uso terapéutico.
US6800287B2 (en)	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (en) *	1998-10-02	2000-04-13	Yeda Research And Development Co., Ltd.	Alternate day administration of copolymer 1 for treating autoimmune diseases
US7083777B1 (en)	1999-04-02	2006-08-01	The Brigham And Women's Hospital, Inc.	Immunomodulating polymers
ATE302020T1 (de) *	2000-01-20	2005-09-15	Yeda Res & Dev	Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
ATE329608T1 (de) *	2000-02-18	2006-07-15	Yeda Res & Dev	Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
ZA200206457B (en) *	2000-02-18	2003-08-13	Yeda Res & Dev	Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) *	2000-06-05	2002-06-20	Yong V. Wee	Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CA2411536A1 (en) *	2000-06-05	2001-12-13	V. Wee Yong	The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
DK1294390T3 (da) *	2000-06-07	2006-04-03	Yeda Res & Dev	Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet
WO2002076503A1 (en) *	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
WO2001097785A2 (en) *	2000-06-20	2001-12-27	Caprion Pharmaceuticals Inc.	Basic copolymers for the treatment of prion-related-disease
IL137460A0 (en) *	2000-07-24	2001-07-24	Yeda Res & Dev	Identifying antigen clusters for monitoring a global state of an immune system
US20040037828A1 (en)	2002-07-09	2004-02-26	Bar-Ilan University	Methods and pharmaceutical compositions for healing wounds
SV2003000753A (es)	2000-12-05	2003-06-16	Brigham & Womens Hospital	Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
GB2369896A (en)	2000-12-06	2002-06-12	Marconi Comm Ltd	Tunable optical filter actuator
KR100442122B1 (ko) *	2001-07-31	2004-07-30	한국전기연구원	영구 자석을 이용한 브러시리스 발전기
KR100657048B1 (ko) *	2001-12-04	2006-12-12	테바 파마슈티컬 인더스트리즈 리미티드	글라티라머 아세테이트의 효능 측정 방법
CA2469092C (en) *	2001-12-06	2013-02-19	Yeda Research And Development Co. Ltd	Copolymer 1 vaccine and methods for treatment of amyotrophic lateral sclerosis (als)
US20060057107A1 (en) *	2001-12-21	2006-03-16	Shaked Ze Ev	Combination treatment for multiple sclerosis
CA2411786C (en)	2002-11-13	2009-01-27	Brantford Chemicals Inc.	A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
JP5291878B2 (ja)	2003-01-07	2013-09-18	イエダリサーチアンドデベロップメントカンパニーリミテッド	治療的免疫のためのコポリマー１を含む点眼ワクチン
AU2004206120B2 (en) *	2003-01-21	2009-09-24	Yeda Research And Development Co. Ltd.	COP 1 for treatment of inflammatory bowel diseases
EP1603530A1 (en) *	2003-03-04	2005-12-14	Teva Pharmaceutical Industries Limited	Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
AU2004227852B2 (en)	2003-03-31	2010-01-14	The Brigham And Women's Hospital, Inc.	Zwitterionic immunomodulators for the treatment of asthma and allergy
EA200600877A1 (ru) *	2003-10-31	2006-12-29	Тева Фармасьютикал Индастриз, Лтд.	Наночастицы для доставки лекарств
CA2546077C (en)	2003-11-12	2016-07-05	Yeda Research And Development Co. Ltd.	Vaccine and method for treatment of neurodegenerative diseases
PT1701730E (pt)	2003-12-09	2013-11-27	Yeda Res & Dev	Método e vacina compreendendo copolímero 1 para tratamento de distúrbios psiquiátricos
EP1725099A4 (en) *	2004-02-02	2009-08-19	Mixture Sciences Inc	PEPTIDE MIXTURES WITH IMMUNOMODULATIVE ACTIVITY
KR20060125916A (ko) *	2004-03-01	2006-12-06	펩팀문, 인코포레이티드	자가면역 질병을 치료하기 위한 방법 및 조성물
EP1778286A4 (en) *	2004-03-03	2009-04-08	Teva Pharma	COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US20050260770A1 (en) *	2004-04-01	2005-11-24	Cohen Irun R	Antigen array and diagnostic uses thereof
NZ551236A (en)	2004-05-07	2010-11-26	Peptimmune Inc	Methods of treating disease with random copolymers
US20060194725A1 (en) *	2004-05-07	2006-08-31	James Rasmussen	Methods of treating disease with random copolymers
US7655221B2 (en) *	2004-05-07	2010-02-02	Peptimmune, Inc.	Methods of treating disease with random copolymers
EP2332570A1 (en)	2004-06-25	2011-06-15	ID Biomedical Corporation of Quebec	Compositions and methods for treating neurological disorders
HUE028833T2 (en) *	2004-09-09	2017-01-30	Yeda Res & Dev	Polypeptide mixtures, compositions containing them, process for their preparation, and applications
ES2451006T3 (es) *	2004-09-09	2014-03-26	Teva Pharmaceutical Industries Ltd.	Procedimiento para la preparación de mezclas de acetato de trifluoroacetilglatirámero usando ácido bromhídrico purificado
US8324641B2 (en) *	2007-06-29	2012-12-04	Ledengin, Inc.	Matrix material including an embedded dispersion of beads for a light-emitting device
DE602005016292D1 (de) *	2004-10-29	2009-10-08	Sandoz Ag	Verfahren zur herstellung von glatiramer
WO2006057003A2 (en) *	2004-11-29	2006-06-01	Yeda Research And Development Co. Ltd.	Induction of neurogenesis and stem cell therapy in combination with copolymer 1
UA93669C2 (ru) *	2005-02-02	2011-03-10	Тева Фармасьютикл Индастриз, Лтд.	Способ приготовления полипептидной смеси c использованием гидрогенолиза
PL1848415T3 (pl) *	2005-02-17	2013-10-31	Teva Pharma	Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
US20100167983A1 (en) *	2007-10-22	2010-07-01	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
US20060240463A1 (en) *	2005-04-25	2006-10-26	Rappaport Family Institute For Research In The Medical Sciences	Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007081975A2 (en) *	2006-01-11	2007-07-19	Teva Pharmaceutical Industries, Ltd.	Method of treating multiple sclerosis
US8206726B2 (en)	2006-02-06	2012-06-26	The Brigham And Women's Hospital, Inc.	Zwitterionic polysaccharides for promotion of immune system maturation and health
JP2009536157A (ja)	2006-04-13	2009-10-08	ペプチミューン，インコーポレイテッド	エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
CA2650653C (en) *	2006-04-28	2016-03-29	Momenta Pharmaceuticals, Inc.	Methods of evaluating glatiramer acetate
KR100831796B1 (ko) *	2006-05-29	2008-05-28	엘지전자 주식회사	타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
US9089509B2 (en)	2006-06-28	2015-07-28	Yeda Research And Development Co., Ltd.	Method of treatment of age-related macular degeneration
EP2046817B1 (en) *	2006-07-05	2009-12-16	Momenta Pharmaceuticals, Inc.	Improved process for the preparation of copolymer-1
ES2477232T5 (es)	2007-06-21	2017-11-23	Momenta Pharmaceuticals, Inc.	Análisis de copolímeros
US20090029766A1 (en) *	2007-07-26	2009-01-29	Lutnick Howard W	Amusement gaming access and authorization point
WO2009016643A1 (en) *	2007-07-31	2009-02-05	Natco Pharma Limited	Process for the preparation glatiramer acetate (copolymer-1)
AP3467A (en)	2007-10-16	2015-11-30	Peptimmune Inc	Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
WO2009062132A2 (en)	2007-11-09	2009-05-14	California Institute Of Technology	Immunomodulating compounds and related compositions and methods
WO2009070298A1 (en) *	2007-11-28	2009-06-04	Teva Pharmaceutical Industries, Ltd.	Method of delaying the onset of clinically definite multiple sclerosis
EP2277050B2 (en)	2008-04-16	2022-09-28	Momenta Pharmaceuticals, Inc.	Analysis of amino acid copolymer compositions
HUE025042T2 (en) *	2008-08-07	2016-07-28	Sigma Aldrich Co Llc	High-yield production of low molecular weight polylysine and poliornitine
WO2010017292A1 (en) *	2008-08-07	2010-02-11	Scinopharm Taiwan, Ltd.	Synthesis of glatiramer acetate
AR074881A1 (es)	2008-12-24	2011-02-16	Synthon Bv	Un proceso para purificar una mezcla de polimeros
RU2011144566A (ru)	2009-04-03	2013-05-10	Момента Фармасьютикалз, Инк.	Контроль сополимерных композиций
AU2009347384B2 (en)	2009-06-04	2014-10-23	Council Of Scientific & Industrial Research	A process for the preparation of copolymer - 1 (Cop-I), composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine-drug for the treatment of multiple sclerosis
US8920373B2 (en)	2009-07-15	2014-12-30	Teva Pharmaceutical Industries, Ltd.	Reduced volume formulation of glatiramer acetate and methods of administration
CA2697570C (en) *	2009-07-15	2011-11-01	Teva Pharmaceutical Industries, Ltd.	Reduced volume formulation of glatiramer acetate and methods of administration
US8691790B2 (en) *	2009-07-27	2014-04-08	James Layne Boucher	Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
DE202010018377U1 (de)	2009-08-20	2016-02-25	Yeda Research And Development Co., Ltd.	Niedrigfrequente therapie mit glatirameracetat
CA2784394C (en)	2010-01-04	2016-12-13	Mapi Pharma Limited	Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
US8377885B2 (en)	2010-01-04	2013-02-19	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP2523668A1 (en)	2010-01-13	2012-11-21	Ramot at Tel-Aviv University Ltd	Treatment of multiple sclerosis
US8759302B2 (en) *	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US20110251156A1 (en)	2010-04-07	2011-10-13	Yue Shen	Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US20130281663A1 (en) *	2010-04-27	2013-10-24	Dr. Reddy's Laboratories, Inc.	Preparation of polypeptides and salts thereof
CA2800174A1 (en)	2010-05-20	2011-11-24	June L. Round	Antigen specific tregs and related compositions, methods and systems
CA2806997A1 (en) *	2010-07-29	2012-02-02	Dr. Reddy's Laboratories Ltd.	Glatiramer acetate molecular weight markers
US8709433B2 (en)	2010-10-11	2014-04-29	Teva Pharmaceutical Industries Ltd.	Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
US9029507B2 (en)	2011-02-14	2015-05-12	Usv Limited	Copolymer-1, process for preparation and analytical methods thereof
EP2699317B1 (en) *	2011-04-21	2016-08-10	Mapi Pharma Limited	Random pentapolymer for treatment of autoimmune diseases
WO2012150495A1 (en)	2011-05-05	2012-11-08	National Institute Of Immunology	Synthetic peptides and random copolymers for the treatment of autoimmune disorders
WO2013009885A2 (en)	2011-07-11	2013-01-17	Momenta Pharmaceuticals, Inc.	Evaluation of copolymer diethylamide
WO2013009864A1 (en)	2011-07-11	2013-01-17	Momenta Pharmaceuticals, Inc.	Structure assessment of heterogeneous polypeptide mixtures
EP2731617A4 (en)	2011-07-12	2015-07-01	Brigham & Womens Hospital	LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USING SAME
US8575198B1 (en)	2011-09-07	2013-11-05	Momenta Pharmaceuticals, Inc.	In-process control for the manufacture of glatiramer acetate
JP2014530819A (ja)	2011-10-10	2014-11-20	テバファーマシューティカルインダストリーズリミティド	酢酸グラチラマーに対する臨床的応答性を予測するために有用な一塩基多形
EP2642290A1 (en)	2012-03-19	2013-09-25	Synthon BV	Glatiramer acetate human monocytic cell line-based potency assay
WO2013139728A1 (en)	2012-03-19	2013-09-26	Synthon Bv	Glatiramer acetate human monocyte cell-based potency assay
US20140045740A1 (en) *	2012-08-13	2014-02-13	Momenta Pharmaceuticals, Inc.	Analysis of glatiramer acetate
MX2015004563A (es)	2012-10-10	2015-07-14	Teva Pharma	Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
WO2014060942A2 (en) *	2012-10-20	2014-04-24	Mahesh Kandula	Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
WO2014128079A1 (en)	2013-02-19	2014-08-28	Synthon B.V.	Glatiramer acetate multidose formulation
SI2774639T1 (sl)	2013-03-08	2015-05-29	Teva Pharmaceutical Industries, Ltd.	Injektorska naprava za brizgo, primerna za večkratno uporabo
EP2774640B1 (en)	2013-03-08	2014-12-31	Teva Pharmaceutical Industries, Ltd.	Re-useable injector device for syringe
US10344330B2 (en)	2013-03-14	2019-07-09	Mylan Inc.	Glatiramer acetate response biomarker mRNA potency assay
WO2014173463A1 (en)	2013-04-26	2014-10-30	Synthon Bv	Glatiramer acetate human monocytic cell line-based potency assay
EP2994161B1 (en)	2013-05-10	2020-10-28	California Institute of Technology	Probiotic prevention and treatment of colon cancer
CN103265624B (zh) *	2013-05-27	2015-04-22	成都圣诺生物制药有限公司	格拉替雷的制备方法
CN104371012A (zh) *	2013-08-12	2015-02-25	深圳翰宇药业股份有限公司	一种合成醋酸格拉替雷的方法
UY35790A (es)	2013-10-21	2015-05-29	Teva Pharma	Marcadores genéticos que predicen la respuesta al acetato de glatiramer
AU2014340010B2 (en)	2013-10-24	2021-05-27	Mylan Inc.	Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
US10545144B2 (en)	2013-12-31	2020-01-28	Yeda Research And Development Co., Ltd.	Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
KR20200029627A (ko)	2014-03-12	2020-03-18	예다 리서치 앤드 디벨럽먼트 캄파니 리미티드	Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
CN104844697B (zh)	2014-09-26	2018-10-23	深圳翰宇药业股份有限公司	醋酸格拉替雷的制备方法
US9155775B1 (en)	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
EP3265814B1 (en)	2015-03-01	2020-11-18	Immunarray Ltd.	Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
US11331335B2 (en)	2015-06-10	2022-05-17	California Institute Of Technology	Sepsis treatment and related compositions methods and systems
JP6918365B2 (ja)	2015-08-19	2021-08-11	プレジデントアンドフェローズオブハーバードカレッジ	脂質化ｐｓａ組成物および方法
ES2744179T3 (es)	2015-09-24	2020-02-24	Chemi Spa	Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas
ES2707500T3 (es)	2015-11-23	2019-04-03	Chemi Spa	Análisis mediante RP-HPLC de mezclas de polipéptidos complejos
CN107522774B (zh) *	2016-06-22	2021-07-02	深圳翰宇药业股份有限公司	一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
EP3478300B1 (en)	2016-06-30	2022-08-24	Stem Cell Medicine Ltd.	Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
US11491181B2 (en)	2016-07-15	2022-11-08	President And Fellows Of Harvard College	Glycolipid compositions and methods of use
EP3503907B1 (en)	2016-08-28	2024-03-13	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh)	2016-08-31	2019-07-05	Mapi医药公司	包含醋酸格拉替雷的储库系统
WO2018178973A1 (en)	2017-03-26	2018-10-04	Mapi Pharma Ltd.	Glatiramer depot systems for treating progressive forms of multiple sclerosis
CN110709091A (zh)	2017-05-15	2020-01-17	干细胞医药有限公司	使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
WO2018211498A1 (en)	2017-05-15	2018-11-22	Stem Cell Medicine Ltd.	Treatment of multiple sclerosis with adipose-derived stem cells
WO2019175869A1 (en)	2018-03-12	2019-09-19	Yeda Research And Development Co. Ltd	Treatment of a heart disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL36670A (en) *	1971-04-21	1974-09-10	Sela M	Therapeutic basic copolymers of amino acids
US4444760A (en) *	1983-06-17	1984-04-24	Merck & Co., Inc.	Purification and characterization of a protein fibroblast growth factor
JPS6053535A (ja)	1983-09-02	1985-03-27	Nitto Boseki Co Ltd	規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru)	1984-04-28	1985-09-30	Таджикский государственный университет им.В.И.Ленина	Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
EP0378246B1 (en)	1985-06-18	1992-03-11	Emory University	Biologically active copolymers
DD257174A3 (de)	1985-12-20	1988-06-08	Ve Forschungszentrum Biotechno	Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru)	1986-05-30	1995-11-20	Институт Высокомолекулярных Соединений Ан Ссср	Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
US4828706A (en) *	1988-03-07	1989-05-09	Spectrum Medical Industries	Process for performing a dialysis operation
US4908404A (en) *	1988-08-22	1990-03-13	Biopolymers, Inc.	Synthetic amino acid-and/or peptide-containing graft copolymers
DE8900366U1 (de) *	1989-01-13	1989-08-03	Indag Gesellschaft für Industriebedarf mbH, 69214 Eppelheim	Folienbeutel
CA2009996A1 (en) *	1989-02-17	1990-08-17	Kathleen S. Cook	Process for making genes encoding random polymers of amino acids
SU1690368A1 (ru)	1989-07-20	1995-08-20	Институт Высокомолекулярных Соединений Ан Ссср	Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de)	1989-09-14	1991-03-28	Roehm Gmbh	Verfahren zur herstellung eines komplexierten arzneimittels
JP2653255B2 (ja) *	1990-02-13	1997-09-17	武田薬品工業株式会社	長期徐放型マイクロカプセル
EP0613496B1 (en) *	1991-11-12	1999-01-20	E.I. Du Pont De Nemours And Company	Collagen-like polypeptides
US5800808A (en) *	1994-05-24	1998-09-01	Veda Research And Development Co., Ltd.	Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) *	1997-01-10	2001-04-10	Yeda Research And Development Co. Ltd.	Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO1998049939A1 (en)	1997-05-06	1998-11-12	Quanta Vision	Tissue analysis apparatus
ATE302020T1 (de) *	2000-01-20	2005-09-15	Yeda Res & Dev	Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
US6936539B2 (en) *	2003-09-24	2005-08-30	Micron Technology, Inc.	Antireflective coating for use during the manufacture of a semiconductor device

1995
- 1995-05-22 US US08/447,146 patent/US5800808A/en not_active Expired - Lifetime
- 1995-05-22 IL IL11381295A patent/IL113812A/xx not_active IP Right Cessation
- 1995-05-23 BR BR9507758A patent/BR9507758A/pt active IP Right Grant
- 1995-05-23 DK DK95920632T patent/DK0762888T3/da active
- 1995-05-23 NZ NZ287335A patent/NZ287335A/xx not_active IP Right Cessation
- 1995-05-23 CA CA002191088A patent/CA2191088C/en not_active Expired - Lifetime
- 1995-05-23 CZ CZ19963410A patent/CZ292247B6/cs not_active IP Right Cessation
- 1995-05-23 GE GEAP19953466A patent/GEP20002205B/en unknown
- 1995-05-23 AT AT95920632T patent/ATE212857T1/de active
- 1995-05-23 UA UA96114382A patent/UA62908C2/uk unknown
- 1995-05-23 DE DE69525340T patent/DE69525340T2/de not_active Expired - Lifetime
- 1995-05-23 PT PT95920632T patent/PT762888E/pt unknown
- 1995-05-23 WO PCT/US1995/006551 patent/WO1995031990A1/en active IP Right Grant
- 1995-05-23 HU HU9603243A patent/HU223473B1/hu active Protection Beyond IP Right Term
- 1995-05-23 JP JP7530519A patent/JPH10500955A/ja active Pending
- 1995-05-23 PL PL95317331A patent/PL181026B1/pl unknown
- 1995-05-23 BR BRPI9507758-8A patent/BRPI9507758B1/pt unknown
- 1995-05-23 SI SI9530577T patent/SI0762888T1/xx unknown
- 1995-05-23 EP EP95920632A patent/EP0762888B1/en not_active Expired - Lifetime
- 1995-05-23 CN CNB200410064296XA patent/CN1310673C/zh not_active Expired - Lifetime
- 1995-05-23 DE DE2002199030 patent/DE10299030I1/de active Pending
- 1995-05-23 TJ TJ96000421A patent/TJ392B/xx unknown
- 1995-05-23 MD MD97-0024A patent/MD1443G2/ro unknown
- 1995-05-23 ES ES95920632T patent/ES2172586T3/es not_active Expired - Lifetime
- 1995-05-23 SK SK1493-96A patent/SK283699B6/sk not_active IP Right Cessation
- 1995-05-23 KR KR1019960706612A patent/KR100403750B1/ko not_active Expired - Lifetime
- 1995-05-23 CN CNB951941011A patent/CN1174753C/zh not_active Expired - Lifetime
- 1995-05-23 AU AU26021/95A patent/AU2602195A/en not_active Abandoned
- 1995-05-23 EE EE9600170A patent/EE03423B1/xx unknown
1996
- 1996-11-15 FI FI964600A patent/FI120236B/fi not_active IP Right Cessation
- 1996-11-22 NO NO19964976A patent/NO324528B1/no not_active IP Right Cessation
1998
- 1998-02-27 US US09/032,334 patent/US6048898A/en not_active Expired - Lifetime
- 1998-02-27 US US09/032,647 patent/US6054430A/en not_active Expired - Lifetime
- 1998-02-27 US US09/032,616 patent/US5981589A/en not_active Expired - Lifetime
- 1998-07-02 HK HK98108818A patent/HK1008657A1/xx not_active IP Right Cessation
2000
- 2000-01-05 IL IL13389000A patent/IL133890A0/xx not_active IP Right Cessation
- 2000-02-22 US US09/510,466 patent/US6362161B1/en not_active Expired - Lifetime
- 2000-02-22 US US09/510,141 patent/US6342476B1/en not_active Expired - Lifetime
2001
- 2001-12-14 US US10/014,477 patent/US6620847B2/en not_active Expired - Lifetime
2002
- 2002-07-29 NL NL300096C patent/NL300096I2/nl unknown
- 2002-08-05 LU LU90987C patent/LU90987I2/fr unknown
- 2002-08-09 JP JP2002233094A patent/JP3715600B2/ja not_active Expired - Lifetime
2003
- 2003-07-10 US US10/615,865 patent/US6939539B2/en not_active Expired - Lifetime
2005
- 2005-04-05 US US11/098,432 patent/US7199098B2/en not_active Expired - Fee Related
2007
- 2007-01-23 US US11/656,505 patent/US7625861B2/en not_active Expired - Fee Related
2011
- 2011-09-26 US US13/244,737 patent/US8367605B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1626238A (zh)	2005-06-15
NO964976L (no)	1997-01-23
HUT75672A (en)	1997-05-28
UA62908C2 (uk)	2004-01-15
TJ392B (en)	2004-10-13
SK149396A3 (en)	1997-08-06
CA2191088A1 (en)	1995-11-30
EP0762888B1 (en)	2002-02-06
US20050171286A1 (en)	2005-08-04
AU2602195A (en)	1995-12-18
FI964600L (fi)	1996-12-05
KR970703154A (ko)	1997-07-03
US20040106554A1 (en)	2004-06-03
DE10299030I1 (de)	2003-01-23
US6342476B1 (en)	2002-01-29
IL113812A0 (en)	1995-08-31
KR100403750B1 (ko)	2006-02-13
WO1995031990A1 (en)	1995-11-30
NZ287335A (en)	1999-02-25
FI964600A0 (fi)	1996-11-15
US5981589A (en)	1999-11-09
CN1310673C (zh)	2007-04-18
MD1443G2 (ro)	2000-11-30
US6939539B2 (en)	2005-09-06
ATE212857T1 (de)	2002-02-15
EP0762888A4 (no)	1997-04-16
SK283699B6 (sk)	2003-12-02
US7625861B2 (en)	2009-12-01
MD1443F1 (en)	2000-04-30
EE03423B1 (et)	2001-06-15
IL133890A0 (en)	2001-04-30
HU223473B1 (hu)	2004-07-28
LU90987I2 (fr)	2003-02-25
JPH10500955A (ja)	1998-01-27
US6620847B2 (en)	2003-09-16
PT762888E (pt)	2002-07-31
NL300096I1 (nl)	2002-10-01
US20030064914A1 (en)	2003-04-03
US5800808A (en)	1998-09-01
CZ341096A3 (en)	1997-06-11
JP3715600B2 (ja)	2005-11-09
NO964976D0 (no)	1996-11-22
NO324528B1 (no)	2007-11-12
CN1152874A (zh)	1997-06-25
DK0762888T3 (da)	2002-05-27
PL317331A1 (en)	1997-04-01
US6362161B1 (en)	2002-03-26
HU9603243D0 (en)	1997-01-28
CN1174753C (zh)	2004-11-10
DE69525340T2 (de)	2002-09-19
CA2191088C (en)	2004-09-28
EE9600170A (et)	1997-06-16
SI0762888T1 (en)	2002-08-31
BR9507758A (pt)	1997-09-23
US20070117757A1 (en)	2007-05-24
US6048898A (en)	2000-04-11
JP2003105000A (ja)	2003-04-09
NL300096I2 (nl)	2003-02-03
US6054430A (en)	2000-04-25
IL113812A (en)	2000-06-29
DE69525340D1 (de)	2002-03-21
HK1008657A1 (en)	1999-05-14
GEP20002205B (en)	2000-08-25
US8367605B2 (en)	2013-02-05
BRPI9507758B1 (pt)	2021-03-16
US20120077754A1 (en)	2012-03-29
CZ292247B6 (cs)	2003-08-13
US7199098B2 (en)	2007-04-03
EP0762888A1 (en)	1997-03-19
PL181026B1 (pl)	2001-05-31
ES2172586T3 (es)	2002-10-01

Publication	Publication Date	Title
FI120236B (fi)	2009-08-14	Kopolymeeri-1 parannuksia kopolymeerien seoksiin
RU2198900C2 (ru)	2003-02-20	Усовершенствованный сополимер-1 и способ его получения
AU741590B2 (en)	2001-12-06	Copolymer-1 improvements in compositions of copolymers
AU2004202245B2 (en)	2006-06-15	Copolymer-1 Improvements in Compositions of Copolymers
AU775214B2 (en)	2004-07-22	Copolymer-1 improvements in compositions of copolymers
JPH03170498A (ja)	1991-07-24	ペプチドおよびこのペプチドを含有する薬剤
JP2001512449A (ja)	2001-08-21	細胞増殖を阻害するペプチド及びその使用

Legal Events

Date	Code	Title	Description
2009-08-14	FG	Patent granted	Ref document number: 120236 Country of ref document: FI
2015-06-22	MA	Patent expired

Date

Code

Title

Description